Brief: Pharvaris Announces FDA Clinical Hold On PHA121 Clinical Trials In U.S.
22/08/2022 12:55
Aug 22 (Reuters) - Pharvaris NV PHVS.O :
* PHARVARIS ANNOUNCES FDA CLINICAL HOLD ON PHA121 CLINICAL
TRIALS
IN THE U.S.
* PHARVARIS NV- COMPANY PLANS TO PROVIDE ADDITIONAL UPDATES
FOLLOWING INTERACTIONS WITH FDA
* PHARVARIS NV- FDA INDICATED IT WILL PROVIDE A FORMAL
CLINICAL
HOLD LETTER TO PHARVARIS IN APPROXIMATELY 30 DAYS
Source text for Eikon: ID:nGNX5vS17C
Further company coverage: PHVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharvaris
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Pharvaris gains after genetic disorder drug meets late-stage trial goal